Cemiplimab, an antibody targeting the PD-1 molecule, was tested as a first-line monotherapy in a group of patients with advanced NSCLC according to PD-L1 tumour cell expression (in a multicentre, global, open-label phase 3 EMPOWER-Lung 1 study). This evidence concerns the gene CD274 and non-small cell lung carcinoma.